“Fly on the wall”: A mixed methods exploration of the perspectives of those who grew up with a sibling with additional needs

Abstract The experiences of those who grow up with a sibling with additional needs is a largely unexplored area of research. Where research exists, it is often quantitative and based on parental report. Research participants are often siblings of those with autism, learning difficulties, and/or “disability”. Most research is not British and there is little research regarding school experiences. This research aimed to answer three research questions: 1. How much do those who grew up with a sibling with additional needs perceive that their life was affected? This was measured via self-rating scales. 2. What do those who grew up with a sibling with additional needs tell us about their experiences? 3. How can schools better support these children and young people? A mixed methods approach was taken, with a Phase 1 survey, followed by Phase 2 interviews. Surveys were completed by 44 participants, of whom five were interviewed. Quantitative data was analysed using descriptive statistics and qualitative data was analysed using reflexive thematic analysis. Survey respondents were over 18 with no upper limit. Those who were interviewed were aged 18-28. Results demonstrate a heterogeneity of experiences with a mixture of enrichment and challenge. Participants talked about three main themes: • The high and lows of their experiences: happy memories, the impact on their character and the challenges which they, their sibling, and their family experienced. • What it was like to be a “Fly on the wall”, to observe the experiences of family members and the world of disability, whilst rarely shining the spotlight upon themselves. • Being the eldest sister and “second mum” Whilst participants did talk about school, this was usually in the context of witnessing their sibling’s struggles. Key words: siblings, mixed methods, additional needs, eldest sister, school, interviews, surveys, disabilit

Changing trends in mortality among solid organ transplant recipients hospitalized for COVID‐19 during the course of the pandemic

Mortality among patients hospitalized for COVID-19 has declined over the course of the pandemic. Mortality trends specifically in solid organ transplant recipients (SOTR) are unknown. Using data from a multicenter registry of SOTR hospitalized for COVID-19, we compared 28-day mortality between early 2020 (March 1, 2020-June 19, 2020) and late 2020 (June 20, 2020-December 31, 2020). Multivariable logistic regression was used to assess comorbidity-adjusted mortality. Time period of diagnosis was available for 1435/1616 (88.8%) SOTR and 971/1435 (67.7%) were hospitalized: 571/753 (75.8%) in early 2020 and 402/682 (58.9%) in late 2020 (p < .001). Crude 28-day mortality decreased between the early and late periods (112/571 [19.6%] vs. 55/402 [13.7%]) and remained lower in the late period even after adjusting for baseline comorbidities (aOR 0.67, 95% CI 0.46-0.98, p = .016). Between the early and late periods, the use of corticosteroids (≥6 mg dexamethasone/day) and remdesivir increased (62/571 [10.9%] vs. 243/402 [61.5%], p < .001 and 50/571 [8.8%] vs. 213/402 [52.2%], p < .001, respectively), and the use of hydroxychloroquine and IL-6/IL-6 receptor inhibitor decreased (329/571 [60.0%] vs. 4/492 [1.0%], p < .001 and 73/571 [12.8%] vs. 5/402 [1.2%], p < .001, respectively). Mortality among SOTR hospitalized for COVID-19 declined between early and late 2020, consistent with trends reported in the general population. The mechanism(s) underlying improved survival require further study

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment

Robust estimation of bacterial cell count from optical density

Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data

Weed Suppression by Deleterious Rhizobacteria is Affected by Formulation and Soil Properties

Deleterious rhizobacteria (DRB) suppress weed growth in field tests and are considered potential weed biological control agents. This study compared the relative inhibitory action of the DRB Pseudomonas fluorescens strain G2-11 in different formulations, corn gluten meal (CGM), and semolina flour, toward wheat (Triticum aestivum L.), green foxtail (Setaria viridis (L.) Beauv.), and velvetleaf (Abutilon theophrasti Medik) seeds and seedlings in soil assays. Strain G2-11 successfully established in semolina flour as an inoculum formulation but was incompatible with CGM presumably because of antibacterial factors present. The effect of DRB and plant products on seed germination and plant growth were influenced by soil, with the strongest effects seen in fine sandy loam. Semolina flour alone reduced root growth of all target plants except for velvetleaf in silt loam. Green foxtail seed germination was greatly reduced by strain G2-11. With the exception of wheat seedling growth, strain G2-11 enhanced growth-suppressive qualities of semolina flour. Results suggest that natural plant products such as CGM and semolina flour alone and formulated with selected DRB may be important components for weed management considerations in sustainable agriculture

Understanding Black-White Differences in Support for the Racial Invariance Thesis: Lessons Learned From Philadelphia Area Residents

The racial invariance thesis contends causes of offending are similar across race/ethnicity. Black Criminology perceives some tension with this claim, suggesting instead that Black people share a unique worldview due to the racial oppression they face. This worldview may make Black people more receptive to criminological explanations identifying race-specific pathways to committing crime. In the post-Civil Rights era, many white people explain social phenomena like crime in colorblind ways. This study used a random sample of Philadelphia area residents to explore whether Black people were less likely than white people to support the racial invariance thesis. Logistic regression analyses revealed the odds of Black Philadelphians agreeing with the racial invariance thesis were 85% higher than the odds for white Philadelphians. </jats:p